Allogeneic peripheral blood hematopoietic stem cell transplantation for patients with hematologic malignancies.
- Author:
Linghui, XIA
;
Jun, FANG
;
Yong, YOU
;
Tao, GUO
;
Fang, LIU
;
Chun, ZHANG
;
Huijuan, JIANG
;
Ping, ZOU
- Publication Type:Journal Article
- MeSH:
China/epidemiology;
Cyclosporine/*therapeutic use;
Follow-Up Studies;
Graft vs Host Disease/*prevention & control;
Leukemia/*therapy;
Leukemia, Lymphoid/therapy;
Leukemia, Myeloid, Acute/therapy;
*Peripheral Blood Stem Cell Transplantation/adverse effects;
Sepsis/epidemiology;
Sepsis/etiology
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2006;26(1):47-9
- CountryChina
- Language:English
-
Abstract:
To investigate the therapeutic effects and associated complications of allogeneic peripheral blood stem cell transplantation (allo-PBSCT). 40 patients with various malignant hematopoietic diseases received allo-PBSCT. The preparative regimens were based on BUCY2 or modified BUCY2. The acute graft-versus host disease (aGVHD) was prevented by cyclosporin A and short-term MTX regimen in all patients. Two patients from donors with one fully mismatched HLA on DRB1 locus and 4 from unrelated donor also administered Zenapox (CD25 MAb) at dosage of 1 mg/kg every day on the day before transplantation and day 4 after transplantation. These 6 patients were also treated with mycophenolate mofetil (MMF). Transfusion of the donor cells: The median of the transfused nucleated cells was 5.38 x 10(8)/kg and that of the CD34+ cells was 7.8 x 10(6)/kg respectively. All the patients gained hematopoietic reconstruction except one who died of infection before engraftment. Seven patients got II degrees-IV degrees aGVHI) and the incidence was 17.5%. Fourteen patients got cGVHD and the incidence was 53.8% in the patients who survived over 6 months. Twenty-eight patients had fever or other characteristics of infection. The median follow-up time was 13.8 months. The incidence of transplantation related mortality (TRM) was 17.5% and 2 patients relapsed (5.0%). It was concluded that allo-PBSCT can reconstruct hematopoiesis quickly and is a favorable therapeutic method for leukemia.
